CagriSema

News

After CagriSema blow, Novo reveals data for obesity 'triple'

Novo Nordisk's triple-action obesity therapy UBT251, licensed in a $2bn deal last year, achieved almost 20% weight loss in a mid-stage trial.

News

Cartoon graphic of a woman with glasses holding thought bubbles in the palm of either hand, one with a check and one with a cross

Head-to-head trial dents Novo Nordisk's obesity hopes

Novo Nordisk slumps as its two-drug combination for weight loss, CagriSema, performs less well than Eli Lilly's rival Zepbound in a comparative trial.

News

Novo Nordisk's CagriSema tops Ozempic in diabetes trial

Novo Nordisk is considering filing CagriSema for diabetes, in addition to obesity, after it outperformed Ozempic in a head-to-head study.

News

Lilly points to long-lasting weight loss with orforglipron

Lilly breaks new ground for oral GLP-1 agonists with data showing it can help patients keep weight off after treatment with injectable therapies.

News

ADA: Novo continues effort to rehabilitate CagriSema

Novo Nordisk's phase 3 data for CagriSema at ADA raises questions about how weight loss data in obesity trials are interpreted.

News

Novo Nordisk's CagriSema data disappoints investors again

Novo Nordisk's obesity candidate CagriSema has underwhelmed in a second phase 3 trial, sending the company's share into a sharp decline.

After CagriSema blow, Novo reveals data for obesity 'triple'

Head-to-head trial dents Novo Nordisk's obesity hopes

Novo Nordisk's CagriSema tops Ozempic in diabetes trial

Lilly points to long-lasting weight loss with orforglipron

ADA: Novo continues effort to rehabilitate CagriSema

Novo Nordisk's CagriSema data disappoints investors again

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

CagriSema

Editor's Picks